key: cord-0987070-rqtuqjku
authors: Kiszewski, A. E.; Galkina Cleary, E. I.; Jackson, M. J.; Ledley, F. D.
title: The role of NIH funding in vaccine readiness; foundational research and NIH funding underlying candidate SARS-CoV-2 vaccines
date: 2020-09-09
journal: nan
DOI: 10.1101/2020.09.08.20187559
sha: bee55a63b680fdf764ea365a5b69245e023e659f
doc_id: 987070
cord_uid: rqtuqjku

This work characterizes the NIH contribution to vaccine technologies being employed in "warp speed" development of vaccines for COVID-19, as well as the lack of sustained NIH funding for published research against recognized epidemic threats. Using quantitative methods, we examined the advance of published research on ten of the vaccine technologies incorporated in the 165 candidate vaccines entering development through July 2020 as well as the NIH funding that supported this research. Live, attenuated virus, inactivated virus, and adjuvant technologies have been used in successful products since the 1950s and continue to exhibit steady advance. Synthetic (recombinant) vaccines, viral vectors, DNA, and TLR9 agonists as adjuvants emerged since the 1980s, and exhibit a logistic, "S-curve" pattern of growth characteristic of emerging technologies that have passed an analytically-defined established point. In contrast, mRNA, virus-like particle, and nanoparticle technologies show exponential growth characteristic of technologies short of their established points. The body of research and NIH funding for established and emerging vaccine technologies exhibited sustained growth through the late 2010s, supported by >16,000 thousand project years of NIH funding totaling over $17.2 billion (2000-2019), the majority through cooperative agreements and intramural programs. NIH funding for published research on vaccines for recognized zoonotic threats including coronavirus, Zika, Ebola, and dengue, however, has been inconsistent and reactive to disease outbreaks. These data are considered in the context of the high failure rate for candidate vaccines and evidence that technological maturity is a significant factor in the efficiency of product development. Sustained funding for both enabling technologies and vaccine development is essential to ensure a rapid response to COVID and future pandemic threats.

This work examines the advance of research and NIH funding for technologies being employed in "warp speed" development of COVID-19 vaccines in the context of evidence that mature technologies have a greater likelihood of generating successful products. We show that candidate vaccines for COVID-19 employ a variety of established and still-emerging technologies, and identify $17.2 billion in NIH funding for this research from 2000-2019. In contrast, NIH funding for published research for vaccines on recognized pandemic threats has been inconsistent. This work highlights the significance and scale of the NIH contribution to vaccine technologies and the lack of sustained initiatives for vaccine development.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The COVID-19 pandemic has triggered an unprecedented mobilization of global vaccine development efforts. With fatality rates approaching or exceeding 1% (Basu, 2020) , the prospect of long-term sequelae in those who recover (Demertzis et al., 2020; Fiani et al., 2020) , and the high level of population immunity required to halt transmission (Flaxman et al., 2020) , initiatives are expected to proceed at "warp speed" (O'Callaghan, Blatz, & Offit, 2020; Corey et al., 2020) . Vaccine development remains daunting on several fronts despite a vaunted history that includes the global eradication of smallpox, the near elimination of polio (Plotkin, 2014) , the emergence of effective vaccines for seasonal influenza, common childhood diseases, and many other viral and bacterial pathogens. Evidence suggests a failure rate of 94% for vaccines entering clinical development, and that, for successful products, the timeline from preclinical studies to . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20187559 doi: medRxiv preprint approval is 10.7 years (Pronker et al., 2013) . There are a number of reasons for this high failure rate and prolonged developmental timeline.

First, many pathogens have been refractory to vaccine development. High mutation rates render HIV a moving target (Safrit et al., 2016) , while influenza undergoes rapid evolution through both antigenic shift and drift (Kim, Webster, & Webby, 2018) . Strain differences trigger adverse immune responses with dengue virus (WHO, 2018) , and extreme diversity and immunoevasive adaptions have complicated development of vaccines for malaria parasites (Laurens, 2018) . Prior sensitization to non-TB bacterial antigens reduce the BCG vaccine's impact on tuberculosis (Arregui et al., 2016) .

Second, some vaccine development challenges are platform-based and independent of the target. Adverse activation of and interference by Type I interferon has plagued the development of RNA-based vaccines (Pardi et al., 2018; De Beuckelaer et al., 2016) . DNA-based vaccines are prone to insufficient stimulation of immunity (Porter & Raviprakash, 2017) .

Third, development of public health vaccines is classically challenged by issues of cost, stability, and safety. The market for public health vaccines is extremely cost-sensitive given limited public health budgets, the reliance of many regions on non-governmental organizations such as UNICEF or PAHO to purchase vaccines, and the need to vaccinate large numbers of people (Randolph & Barreiro, 2020) to achieve community protection. Moreover, many vaccine technologies produce thermally unstable products requiring refrigeration in lieu of rapid administration. This can dramatically increase distribution costs or render widespread use impractical (Kristensen et al., 2016) .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted September 9, 2020. . https: //doi.org/10.1101 //doi.org/10. /2020 Fourth, given the intense scrutiny of vaccine safety in light of misleading claims and public skepticism of vaccines fomented by the anti-vax movement, widespread public acceptance will require developers to demonstrate an exemplary margin of efficacy and safety (Ball, 2020) .

Finally, it should be noted that general public health measures can also be effective against pandemic disease, and the rapid dissipation of outbreaks related to viruses such as SARS-CoV-1 and Zika have made thorough clinical validation of vaccines impossible (Thomas & Barrett, 2020) .

This work is predicated on innovation research across many different fields demonstrating how the maturation level or readiness of a technology is a critical determinant in its ability to generate products that successfully meet market needs (Christensen, 1992; Christensen, 1997; GAO 1999; Clausing & Holmes, 2010; Foster, 1982; McNamee & Ledley, 2012) . Our previous work has explored the applicability of this principle to drug development using a bibliometric model for the maturation of basic, biomedical research on novel drug targets or therapeutic modalities based on the rate of publication (McNamee, Walsh, & Ledley, 2017) . Studies on the development of more than 500 approved drugs have shown that few targeted therapeutics are successfully developed before research on both the drug target and the therapeutic modality have passed an analytically derived established point, and that the timelines of development are significantly shorter when clinical trials commence after this point , McNamee, Walsh, & Ledley, 2017 , Ledley et al., 2014 .

Additional studies have examined the scale of NIH funding for this body of enabling, basic research (Cleary et al., 2018; . These studies show that the NIH contributed more than $230 billion in funding for research related to the 356 drugs approved . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20187559 doi: medRxiv preprint from 2010-2019 or their 218 drug targets. Significantly, more than 85% of this funding was categorized as basic research on the drug targets, rather than research on the drugs themselves.

The present work examines the maturation of the technologies employed in current efforts to develop COVID-19 vaccines. Specifically, we examine the timelines of published research on technologies related to adjuvants, recombinant proteins, nucleic acids, attenuated/inactivated virus, viral vectors, and formulations using virus-like particles or nanoparticles, the maturity of this research at the end of 2019, and the NIH funding that contributed to this research. We also examine the timelines of research directed towards vaccines for coronaviruses and three unrelated viral pathogens that have been associated with epidemic transmission (Zika, Ebola, and dengue). We consider the impact of this prior research on accelerated efforts to develop a vaccine for COVID-19, and the importance of sustained public sector funding in establishing a foundation for responding to pandemic outbreaks.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20187559 doi: medRxiv preprint

As of July 31, 2020, the WHO listed 165 candidate vaccines against COVID-19: six in Phase 3 trials, twenty in Phase 1 and/or 2, and 139 in various stages of preclinical development (WHO, 2020) . PubMed searches were performed for ten prevalent vaccine technologies from the portfolio of products described in the WHO report. The technologies examined and number of research publications related to each topic are shown in Table 1 . Cumulative publications over time are shown in Figure 1A .

Several viral technologies involving whole virus preparations, including live/attenuated and killed/inactivated viral vaccines, as well as non-specific adjuvants, predate the modern era. These are used in classical vaccines including polio, influenzas, MMR, and others that emerged as prominent elements of public health in the 1950s. Research on these technologies has accumulated steadily since 1980 ( Figure 1A ). Inactivated viral approaches accounted for four of the first ten candidate vaccines to enter human clinical trials against COVID-19, but only 12 (7.3%) candidate vaccines as of July 31, 2020.

Synthetic vaccines employing recombinant protein subunits emerged in the 1980s, capitalizing on the advances in large-scale protein production and purification. Exponential growth of research on synthetic vaccines was evident after 1985 followed by steady growth from the mid-1990s to the present time ( Figure 1A ). While only one of the first ten COVID-19 candidate vaccines to enter clinical trials employed these technologies, recombinant protein antigens are incorporated in 66 (40%) of candidate vaccines as of July 31, 2020.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 9, 2020. . https://doi.org/10. 1101 Vaccines based on recombinant viral vectors that express immunogens emerged in the mid-1990s as an outgrowth of research on gene therapy and experienced a period of exponential growth and subsequent slowing from the early 2000s to the present ( Figure 1A) . Two of the first ten COVID-19 candidate vaccines to enter human trials were based on recombinant adenoviral vectors. Other vaccines currently in clinical development use other viral vectors, including VSV, measles, Sendai virus, avian paramyxovirus, baculovirus, lentivirus, and influenza. Overall, viral vectors are employed in 31 (19%) candidate vaccines.

DNA-based vaccine technologies emerged in the mid-1990s, also as an outgrowth of research on gene therapy, and exhibited a period of rapid acceleration and subsequent slowing. These technologies involve injection of plasmid or synthetic DNA molecules, with the expectation that the injected DNA will be taken up by cells in the body and express the antigen.

A related nucleic acid-based approach involves direct injection of mRNA, which cells take up and translate into antigenic proteins. This approach derives from early methods for expressing in vitro translated mRNA in Xenopus oocytes, and production of infectious virus through injection of purified viral mRNA into cultured cells (Schlake et al., 2012) . This field has exhibited steady growth with the emergence of advanced nucleotide chemistries, self-replicating mRNA, and improved delivery methods.

One DNA vaccine and two mRNA vaccines were among the earliest candidate vaccines to enter human trials. Both mRNA vaccines were among the first to enter Phase 3 clinical evaluation. Overall, there were 36 (22%) nucleic acid-based vaccines in development as of July 31, 2020, 14 based on DNA and 22 with RNA.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 9, 2020. . https://doi.org/10. 1101 Several other vaccine technologies currently employed in candidate COVID-19 vaccines are also shown in Figure 1A , including lipid nanoparticles and virus-like particles designed to enhance delivery and antigenicity of recombinant proteins as well as the use of novel adjuvants (i.e., toll-like receptor 9 [TLR9] agonists) designed to stimulate specific immune pathways.

These technologies were employed in 24 (15%) of the 165 candidate vaccines under development on July 31, 2020.

The maturity of the seven technologies emerging since 1980 was examined using the Technology Innovation Maturation Evaluation (TIME) model ( Figure 1B ). This model fits the cumulative number of publications to an exponentiated logistic function. Plotted on a log scale, this function exhibits the logistic "S-curve" that is characteristic of technology growth in many different fields, including drug development (Foster, 1982; Christensen, 1992 

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20187559 doi: medRxiv preprint

The NIH RePORTER database was used to identify published research (via PMID) acknowledging NIH funding support, specific projects and project years associated with these publications, and the project costs for those years. The total numbers of PMID, number and percent NIH-funded PMID, project years, and project costs for ten vaccine technologies are shown in Table 1 . We identified a total of 51,530 publications related to these ten vaccine technologies, including 8,420 (16%) associated with NIH funding, comprising 16,358 project years and $17.2 billion in project costs. The NIH contributed the most funding for synthetic (recombinant) vaccines ($9.65 billion) followed by adjuvant research ($5.6 billion), DNA vaccines ($4.6 billion), and live, attenuated virus ($4 billion). More than $1 billion in NIH funding was associated with research on inactivated virus and viral vector-based vaccines as well as TLR9 agonists as adjuvants. More than $500 million was invested in mRNA vaccines, viruslike particles, and nanoparticle-based vaccines combined. The activity code categories for NIH projects associated with published research on vaccine technologies are shown in Figure 3A . While 40% of project years associated with research on these technologies represented investigator-initiated research projects, these accounted for only 8.9% of the total project costs. A greater fraction of funding was associated with cooperative . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20187559 doi: medRxiv preprint agreements (44%), intramural programs (9.4%), and research program projects and centers (22.7%). This pattern differs sharply from that seen for development of new drugs approved from 2010-2019 , where the majority of project years and funding for research on drug targets was associated with investigator-initiated research projects.

However, this pattern does resemble that of molecular research underlying the discovery and development of remdesivir for treatment of COVID-19 (Cleary, Jackson, Folchman-Wagner & Ledley, 2020) . Table 1 shows the number of PMID, NIH-funded PMID, project years, and project costs associated with vaccine development for HIV, which has been the subject of intensive vaccine research since the 1980s, as well as Ebola, Zika, dengue, and coronavirus. Figure . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20187559 doi: medRxiv preprint A single peak of NIH funding associated with publications related to vaccines for Zika was evident, corresponding to the 2015-17 outbreak in South America and the Caribbean that also impacted several US states. Another funding peak was evident following the outbreak of SARS-CoV-1 in Asia and its subsequent spread to Toronto. A rise in funding for publications related to dengue was apparent in 2016, coincident with recognition of the increasing prevalence of this disease, but dropped rapidly coincident with an abrupt decrease in reported cases in 2017 and 2018 (https://www.who.int/news-room/fact-sheets/detail/dengue-and-severe-dengue). These data Figure 3B shows the activity code categories for the NIH projects associated with published research on coronavirus vaccines. While the majority of project years were associated with investigator-initiated research projects, only 14% of project costs were associated with research projects, while 34% went to cooperative agreements, 26% to intramural programs, and 22% to research program projects and centers. Thus, as with NIH funding for research on vaccine technologies, the majority of project costs came through research organized or conducted by government agencies, rather than from investigator-initiated projects.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 9, 2020. and estimate the maturity, or readiness, of these technologies for clinical development. We also describe the NIH contribution to development of these technologies through the end of 2019, as well as support for vaccine development directed towards specific zoonotic threats like coronavirus, Zika, Ebola, and dengue.

Some of the technologies used by COVID-19 candidate vaccines (live attenuated or inactivated virus, non-specific adjuvants) date from the mid-20 th century and have been used to create many successful vaccine products. While we found that the research literature on these technologies continues to grow, there is no evidence of exponential acceleration since 1980, suggesting that these technologies had become well-established before that time.

Research on synthetic (recombinant) vaccines, DNA vaccines, (recombinant) viral vectors, and TLR9 agonist-based adjuvants exhibited an "S-curve" pattern of publication activity when fitted to the TIME model. Their curves' inflection points suggest that each of these technologies was established prior to 2010. In contrast, three technologies-mRNA vaccines, virus-like . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 9, 2020. (Christensen, 1992; Christensen, 1997; McNamee & Ledley, 2012) .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20187559 doi: medRxiv preprint Experience with vaccine development offers many parallels. The success of the Salk vaccine was preceded by several unsuccessful efforts to develop inactivated or attenuated viral vaccines.

Moreover, the roll-out of the Salk vaccine itself was complicated by an outbreak of polio caused by inadequate inactivation of early batches of the product, which led to temporary suspension of the vaccine program months after the vaccine was approved (Blume, 2005) . Similarly, early versions of both RSV and Measles vaccines were associated with enhanced disease on reexposure, reflecting the immature knowledge of vaccines and the immune system in that era . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 9, 2020. . https://doi.org/10. 1101 In this context, the over-representation of mRNA-based vaccines among the leading COVID-19 candidate vaccines is of some concern given the relative immaturity of these technologies as measured by the TIME model. Nucleic acid-based vaccines were able to move more rapidly into clinical trials (WHO, 2020) due to inherent efficiencies in process development and scale up of production of these products. This analysis suggests that there may be substantially more downstream risk of product failure or delay with such immature technologies.

We would also note that there is no licensure track record for adenoviral vaccines, which were also able to rapidly enter clinical trials and progress through the initial development stages. Prior to the emergence of COVID-19, two MERS vaccines utilizing these technologies passed Phase 1 trials before the waning of these diseases precluded further testing (Modjarrad et al., 2019; Folegatti et al., 2020) .

The cost of vaccine discovery and development typically relies on both public and private sector investments. A 1997 report by the National Vaccine Advisory Committee concluded that "two thirds of all new vaccines provided worldwide have been produced by a US network of independent industrial, governmental, and academic partners engaged in vaccine research and development" (NVAC, 1997) . A 2001 report by the World Bank, working with Gavi, the Vaccine Alliance, described the role of public sector institutions as being primarily focused on basic science "measured by the number and value of the research manuscripts they publish in the scientific literature" (Batson & Bekier, 2001; Francis, 2010) . In contrast, industry focused on development, manufacture, and marketing of vaccine products (Batson & Bekier, 2001) , and more than 90% of all vaccine doses procured in the past five years have been manufactured by for-profit organizations (WHO, 2019).

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20187559 doi: medRxiv preprint

We also examined NIH funding related to four diseases with recognized epidemic potential including coronavirus, Zika, Ebola, and dengue. The first three were identified by the WHO as pandemic risks in the 2016 "R&D Blueprint for Action to prevent Epidemics" (WHO, 2016) and have been identified as priority epidemic infectious diseases by CEPI (Gouglas et al., 2018) .

Dengue is an endemic pathogen that causes focal outbreaks, which was considered to be outside the scope of the 2016 Blueprint (Mehand et al., 2018) .

A lack of sustainable investment has long been recognized as a limiting factor in developing vaccines for emergent pandemic threats, particularly those initially impacting low-income countries (Rappuoli, Black, & Bloom, 2019) . This problem is exacerbated by the fact that vaccine development typically requires coordinated and sustained funding for research encompassing immunization technologies, disease pathogens, vaccine formulation, and clinical development.

Our analysis describes a sporadic pattern of grant funding related to coronavirus, Zika, Ebola, and dengue viruses, in which outbreaks of disease trigger an increase in grant-funded publication activity, which then wanes rapidly over several years. This is consistent with the observation that investigator-initiated grant mechanisms have not proved to be a robust mechanism for vaccine development (Rappuoli, Black, & Bloom, 2019) .

Our work also demonstrates that while the largest fractions of PMIDs and project years represented investigator-initiated research projects, a majority of the funding was associated with government-initiated research through cooperative agreements or intramural research, or for research capacity through research program projects and centers. This pattern has been observed previously in examining the foundational research underlying development of remdesivir (Cleary, Jackson, Folchman-Wagner, & Ledley, 2020) . This pattern, however, is distinctly . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20187559 doi: medRxiv preprint different from that of NIH funding associated with drugs in other therapeutic areas, where the large majority of research funding involves investigator-initiated research projects or related research program projects and centers . Further research is required to understand the determinants of investigator-initiated versus government-initiated research, and how these different mechanisms contribute to the development of vaccine technologies and vaccines for pandemic threats.

Finally, we would note that there is no demonstrated relationship between the amount of NIH funding and the success of vaccine development initiatives. Despite decades of research and billions of dollars in NIH funding, vaccines have yet to be registered for diseases such as HIV and hepatitis C. In contrast, the NIH contributed little funding to published research on Ebola or dengue viruses, both of which are associated with FDA-approved vaccines.

There are several important limitations to this study. First, this analysis is restricted to research that produces publications in PubMed, which may not capture research described in white papers, reports, patents, regulatory filings, unpublished clinical studies, or trade secrets. This method may also fail to identify publications describing enabling technologies not directly related to vaccines, early research performed before accepted vocabularies emerge, and publications without abstracts in PubMed. Second, it is not possible to associate costs with every NIH-funded publication due to missing data in RePORTER and inconsistencies between publication dates and project years. Moreover, given an estimated lag of up to three years between research funding and publication (Boyack & Jordan, 2011) , funding for research performed since 2018 may be underrepresented in the data collection. Third, this analysis does not account for research funded by agencies outside HHS, particularly DOD or NSF, government . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 9, 2020. . https: //doi.org/10.1101 //doi.org/10. /2020 contracts, other nations, philanthropies, or academic institutions. Nor does it account for the $1.8 billion that the U.S. contributed to Gavi since 2009 (KFF, 2020 or for investments by industry in clinical trials of process development.

The "Operation Warp Speed" and "Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)" initiatives involved funding a variety of different candidate vaccines utilizing different technologies. This work demonstrates that the technologies represented in this portfolio vary significantly in maturity. Inasmuch as technological maturity is often a significant factor in the efficiency and cost of product development, the maturity of individual technologies should be a factor in guiding both expectations for success and investment in different candidate vaccines.

This work highlights the scale and importance of a broad, sustained foundation of NIH funding in the ability to respond to the COVID-19 pandemic. The research that will enable rapid development of a COVID-19 vaccine was not undertaken with such a vaccine in mind, but was often undertaken in unrelated contexts such as basic molecular biology, gene therapy, immunology, or drug delivery. Nevertheless, this funding advanced the maturation of technologies that are now available for application in COVID-19 vaccines. Significantly, the majority of this funding came in the form of government-initiated cooperative agreements or intramural research, rather than investigator-initiated research projects.

In contrast, this work again demonstrates the lack of sustained research and NIH funding related to recognized, epidemic threats, such as coronavirus, may have contributed to the lack of preparedness for the emergence of COVID-19. Further consideration needs to be given to the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20187559 doi: medRxiv preprint mechanisms of funding research on emerging pandemic threats beyond coronavirus (WHO, 2016) to ensure that the technologies are ready to respond.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20187559 doi: medRxiv preprint

Technologies utilized in candidate vaccines against COVID-19 were identified from the WHO "DRAFT Landscape of Candidate COVID-19 vaccines" (WHO, 2020) accessed July 31, 2020.

Viruses with epidemic potential that have been subject to intensive vaccine development initiatives were identified from Plotkin, 2017, and the WHO Blueprint (Plotkin 2017; Mehand et al., 2018) .

Searches were performed in PubMed (www.pubmed.gov; accessed June 3, 2020) using the updated Automatic Term Mapping (May, 2020), initially with Medical Subject Headings (MeSH) terms, and then optimized with Boolean modifiers to increase specificity. PubMed Identifiers (PMIDs) and publication year were recorded for each publication identified.

We then quantified the contribution of NIH funding to publications identified in PubMed using NIH RePORTER (https://exporter.nih.gov/ExPORTER_Catalog.aspx; accessed June 3, 2020) via methods reported in a similar study of drug development (Cleary et al., 2018) . A tabulation of NIH-sponsored research that led to these publications was derived from the RePORTER/ExPORTER format files catalog (NIH, 2020). Wherever possible, each PMID was associated with a project year corresponding to the project number and fiscal year in the "Link Tables for Project to Publication Associations." The "Project Data Table" provided the fiscal year costs for each project (since 2000). Costs were derived for each project year corresponding to the program cost associated with PMIDs via the Project Table. Activity codes associated with the core project indicated the type of grant.

Publications occurring before the first year of the grant award or more than four years after the last year of the grant were excluded. Publications 1-4 years after the last year of the grant were . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 9, 2020. . https://doi.org/10. 1101 associated with the project costs of the last year. Grant categories were derived from "NIH Types of Grant Programs 2020" (https://grants.nih.gov/grants/funding/funding_program.htm; accessed May, 2020). Costs are given in constant dollars inflation adjusted to 2018 using the U.S. Bureau of Labor Statistics All Urban Consumer Prices (Current Series) (https://www.bls.gov/data/; accessed May, 2020). All analyses were performed in PostgreSQL and Excel.

The relative maturity of seven critical technologies emerging since 1980 was examined by fitting the bibliographic Technology Innovation Maturation Evaluation (TIME) model, an exponentiated logistic function described previously, to a time series of publication records derived from PubMed searches (McNamee, Walsh, & Ledley, 2017) . The equation has the form:

Where N is the number of publications, L is the presumed upper limit of publications, r is the growth rate, t is time, and t 0 is midpoint of the exponential growth. This asymmetric sigmoidal function exhibits the common logistic sigmoid function over log scales. The parameters were fit to time-series publication data using a non-linear least squares implementation of the Levenberg-Marquardt algorithm (LMFIT, version 1.0.1).

The initiation and established points, representing the beginning and end of the exponential growth phase are defined as the points of maximum and minimum acceleration respectively, or logN''(t) max,min . These points are analytically determined by:

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20187559 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20187559 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 9, 2020 . . https://doi.org/10.1101 lipoplex vaccines to elicit cytolytic T cell responses." Molecular Therapy 24 (11):2012-2020. Decaro, Nicola, Campolo, Marco, Mari, Viviana, Desario, Costantina, Colaianni, Maria Loredana, Di Trani, Livia, Cordioli, Paolo, and Buonavoglia, Canio. 2009 CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20187559 doi: medRxiv preprint non-randomised, uncontrolled, Phase 1 trial." The Lancet Infectious Diseases doi.org/10.1016/S1473-3099(20) 30160-2, Foster, Richard N. 1982 . "Effective R&D operations in the'80s: boosting the payoff from R&D." . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 9, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20187559 doi: medRxiv preprint  T  a  b  l  e  1  .  P  u  b  l  i  c  a  t  i  o  n  s  i  n  P  u  b  M  e  d  (  P  M  I  D  )  a  n  d  N  I  H  f  u  n  d  i  n  g  a  s  s  o  c  i  a  t  e  d  w  i  t  h  r  e  s  e  a  r  c  h  o  n  t  e  c  h  n  o  l  o  g  i  e  s  u  s  e  d  i  n  c  a  n  d  i  d  a  t  e  C  O  V  I  D  -1  9  v  a  c  c  i  n  e  s  a  s  w  e  l  l  a  s  v  a  c  c  i  n  e  d  e  v  e  l  o  p  m  e  n  t  f  o  r  s  e  l  e  c  t  e  d  e  p  i  d  e  m  i  c  t  h  r  e  a  t . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted September 9, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20187559 doi: medRxiv preprint

On the impact of masking and blocking hypotheses for measuring the efficacy of new tuberculosis vaccines

Anti-vaccine movement could undermine efforts to end coronavirus pandemic, researchers warn

Estimating the infection fatality rate among symptomatic Covid-19 cases in the United States: Study estimates the COVID-19 infection fatality rate at the US county level

Vaccines where they're needed

As technologies for nucleotide therapeutics mature, products emerge

Landscape of innovation for cardiovascular pharmaceuticals: From basic science to new molecular entities

Lock in, the state and vaccine development: Lessons from the history of the polio vaccines

Metrics associated with NIH funding: A high-level view

Exploring the limits of the technology S curve. Part I: component technologies

The Innovator's Dilemma: When New Technologies Cause Great Firms to Fail

Technology readiness

Contribution of NIH funding to new drug approvals 2010-2016

Foundational research and NIH funding enabling Emergency Use Authorization of remdesivir for COVID-19

Government as the First Investor in Biopharmaceutical Innovation: Evidence From New Drug Approvals 2010-2019

A strategic approach to COVID-19 vaccine R&D

Type I interferons interfere with the capacity of mRNA

Development of a SARS coronavirus vaccine from recombinant spike protein plus delta inulin adjuvant

The WHO R&D blueprint: 2018 review of emerging infectious diseases requiring urgent research and development efforts

MERS-CoV vaccine candidates in development: The current landscape

Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a Phase 1, open-label, single-arm, dose-escalation trial

Definitions of Research and Development: An Annotated Compilation of Official Sources

Estimates of Funding for Various Research, Condition, and Disease Categories (RCDC)

Research portfolio online reporting tools (RePORTER), ExPORTER data catalog

United States vaccine research: a delicate fabric of public and private collaboration

Developing a SARS-CoV-2 vaccine at warp speed

Bentley University. The authors thank Prateet Shah for his contributions to this manuscript as well as Drs. Michael Boss and Nancy Hsiung for their constructive suggestions.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20187559 doi: medRxiv preprint CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 9, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20187559 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20187559 doi: medRxiv preprint . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20187559 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted September 9, 2020. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)The copyright holder for this preprint this version posted September 9, 2020. . https://doi.org/10.1101/2020.09.08.20187559 doi: medRxiv preprint